These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 22490875)

  • 1. Immunosuppressive regimen and interstitial fibrosis and tubules atrophy at 12 months postrenal transplant.
    Gelens MA; Steegh FM; van Hooff JP; van Suylen RJ; Nieman FH; van Heurn LW; Peutz-Kootstra CJ; Christiaans MH
    Clin J Am Soc Nephrol; 2012 Jun; 7(6):1010-7. PubMed ID: 22490875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sirolimus-based triple immunosupression with antithymocyte globulin induction in expanded criteria donor kidney transplantation.
    Uslu A; Nart A; Taşli FA; Postaci H; Aykas A; Doğan M; Sahin T
    Nephrology (Carlton); 2008 Feb; 13(1):80-6. PubMed ID: 18199109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subclinical Lesions and Donor-Specific Antibodies in Kidney Transplant Recipients Receiving Tacrolimus-Based Immunosuppressive Regimen Followed by Early Conversion to Sirolimus.
    de Sandes-Freitas TV; Felipe CR; Campos ÉF; de Lima MG; Soares MF; de Franco MF; Aguiar WF; Tedesco-Silva H; Medina-Pestana JO
    Transplantation; 2015 Nov; 99(11):2372-81. PubMed ID: 25929604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renin-Angiotensin System Blockage and Avoiding High Doses of Calcineurin Inhibitors Prevent Interstitial Fibrosis and Tubular Atrophy in Kidney Transplant Recipients.
    Sayin B; Canver B; Gurlek Demirci B; Colak T; Ozdemir BH; Haberal M
    Exp Clin Transplant; 2017 Feb; 15(Suppl 1):32-36. PubMed ID: 28260428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteinuria among primarily sirolimus treated live-donor renal transplant recipients' long-term experience.
    Hamdy AF; Bakr MA; Ghoneim MA
    Exp Clin Transplant; 2010 Dec; 8(4):283-91. PubMed ID: 21143093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlations with six-month protocol biopsy findings in pediatric transplant recipients on low- and regular-dose CNI regimens.
    Kanzelmeyer NK; Ahlenstiel T; Kreuzer M; Becker JU; Pape L
    Clin Transplant; 2013; 27(2):319-23. PubMed ID: 23414365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Donor-Specific Anti-Human Leukocyte Antigens Antibodies, Acute Rejection, Renal Function, and Histology in Kidney Transplant Recipients Receiving Tacrolimus and Everolimus.
    Ferreira A; Felipe C; Cristelli M; Viana L; Basso G; Stopa S; Mansur J; Ivani M; Bessa A; Ruppel P; Aguiar W; Campos E; Gerbase-DeLima M; Proença H; Tedesco-Silva H; Medina-Pestana J
    Am J Nephrol; 2017; 45(6):497-508. PubMed ID: 28511172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of early conversion from tacrolimus to sirolimus on chronic allograft changes in kidney recipients on rapid steroid withdrawal.
    Heilman RL; Cortese C; Geiger XJ; Younan K; Wadei HM; Mai ML; Reddy KS; Gonwa TA
    Transplantation; 2012 Jan; 93(1):47-53. PubMed ID: 22067270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
    Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
    Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of cytomegalovirus viremia on subclinical rejection or interstitial fibrosis and tubular atrophy in protocol biopsy at 3 months in renal allograft recipients managed by preemptive therapy or antiviral prophylaxis.
    Reischig T; Jindra P; Hes O; Bouda M; Kormunda S; Treska V
    Transplantation; 2009 Feb; 87(3):436-44. PubMed ID: 19202451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes in African American kidney transplant patients receiving tacrolimus and mycophenolic acid immunosuppression.
    Narayanan M; Pankewycz O; El-Ghoroury M; Shihab F; Wiland A; McCague K; Chan L
    Transplantation; 2013 Feb; 95(4):566-72. PubMed ID: 23423268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors associated with progression of interstitial fibrosis in renal transplant patients receiving tacrolimus and mycophenolate mofetil.
    Rush DN; Cockfield SM; Nickerson PW; Arlen DJ; Boucher A; Busque S; Girardin CE; Knoll GA; Lachance JG; Landsberg DN; Shapiro RJ; Shoker A; Yilmaz S
    Transplantation; 2009 Oct; 88(7):897-903. PubMed ID: 19935461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term renal transplant function in recipient of simultaneous kidney and pancreas transplant maintained with two prednisone-free maintenance immunosuppressive combinations: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus.
    Gallon LG; Winoto J; Chhabra D; Parker MA; Leventhal JR; Kaufman DB
    Transplantation; 2007 May; 83(10):1324-9. PubMed ID: 17519781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year.
    Ciancio G; Burke GW; Gaynor JJ; Mattiazzi A; Roth D; Kupin W; Nicolas M; Ruiz P; Rosen A; Miller J
    Transplantation; 2004 Jan; 77(2):244-51. PubMed ID: 14742989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A prospective, randomized trial of single-drug versus dual-drug immunosuppression in heart transplantation: the tacrolimus in combination, tacrolimus alone compared (TICTAC) trial.
    Baran DA; Zucker MJ; Arroyo LH; Camacho M; Goldschmidt ME; Nicholls SJ; Prevost-Fernandez J; Carr C; Adams L; Pardi S; Hou V; Binetti M; McCahill J; Chichetti J; Viloria V; Sanagustin MG; Ebuenga-Smith J; Mele L; Martin A; Blicharz D; Wolski K; Olesnicky L; Qian F; Gass AL; Cohen M
    Circ Heart Fail; 2011 Mar; 4(2):129-37. PubMed ID: 21216835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tacrolimus-based, steroid-free regimens in renal transplantation: 3-year follow-up of the ATLAS trial.
    Krämer BK; Klinger M; Vítko Š; Glyda M; Midtvedt K; Stefoni S; Citterio F; Pietruck F; Squifflet JP; Segoloni G; Krüger B; Sperschneider H; Banas B; Bäckman L; Weber M; Carmellini M; Perner F; Claesson K; Marcinkowski W; Ostrowski M; Senatorski G; Nordström J; Salmela K
    Transplantation; 2012 Sep; 94(5):492-8. PubMed ID: 22858806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thymoglobulin induction and sirolimus versus tacrolimus in kidney transplant recipients receiving mycophenolate mofetil and steroids.
    Glotz D; Charpentier B; Abramovicz D; Lang P; Rostaing L; Rifle G; Vanrenterghem Y; Berthoux F; Bourbigot B; Delahousse M; Chalopin JM; Cassuto E; Lefrançois N
    Transplantation; 2010 Jun; 89(12):1511-7. PubMed ID: 20386144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal function and histology in kidney transplant patients receiving tacrolimus and sirolimus or mycophenolate mofetil.
    Kamar N; Van TT; Ribes D; Modesto A; Cointault O; Lavayssière L; Ader JL; Durand D; Rostaing L
    Exp Clin Transplant; 2006 Dec; 4(2):532-6. PubMed ID: 17238854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early steroid withdrawal therapy in renal transplant recipients: a steroid-free sirolimus and CellCept-based calcineurin inhibitor-minimization protocol.
    Jaber JJ; Feustel PJ; Elbahloul O; Conti AD; Gallichio MH; Conti DJ
    Clin Transplant; 2007; 21(1):101-9. PubMed ID: 17302598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utility of Serial Protocol Biopsies Performed After 1 Year in Predicting Long-Term Kidney Allograft Function According to Histologic Phenotype.
    Zachariah MS; Dwivedi AK; Yip CS; Chang SS; Gundroo A; Venuto RC; Tomaszewski J; Patel SK; Sharma R
    Exp Clin Transplant; 2018 Aug; 16(4):391-400. PubMed ID: 29206090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.